KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Return on Equity (2016 - 2025)

Historic Return on Equity for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Q3 2025 value amounting to 0.02%.

  • Supernus Pharmaceuticals' Return on Equity fell 800.0% to 0.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.02%, marking a year-over-year decrease of 800.0%. This contributed to the annual value of 0.08% for FY2024, which is 700.0% up from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Return on Equity stood at 0.02%, which was down 800.0% from 0.06% recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Return on Equity high stood at 0.15% for Q1 2021, and its period low was 0.02% during Q3 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' median Return on Equity value was 0.06% (recorded in 2024), while the average stood at 0.06%.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Return on Equity crashed by -1100bps in 2021, and later skyrocketed by 800bps in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Return on Equity (Quarter) stood at 0.07% in 2021, then grew by 6bps to 0.07% in 2022, then plummeted by -98bps to 0.0% in 2023, then surged by 5062bps to 0.07% in 2024, then tumbled by -125bps to 0.02% in 2025.
  • Its Return on Equity was 0.02% in Q3 2025, compared to 0.06% in Q2 2025 and 0.06% in Q1 2025.